Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625217 · ClinicalTrials.gov registry record · NA
Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT05625217: Completed NA study, sponsored by University of California, Davis.
NCT05625217 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05625217, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The overall goal of this research study is to understand how 18F-fluorodeoxyglucose (FDG), a radioactive sugar behaves in head and neck cancer (HNC) and inflammation immediately following injection and at many hours post-injection, with the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER).
Primary Outcome
The retention index based on the SUVmax for Oral Cancer and Radiotherapy-induced inflammation
Interventions
- DIAGNOSTIC_TEST Total Body PET/CT Imagin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2024-11-20 |
| Phase | NA |
What the finished NCT05625217 record still lists
NCT05625217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Total Body PET/CT Imagin is the first listed.
NCT05625217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05625217 about?
NCT05625217 is a clinical study titled "Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer". The overall goal of this research study is to understand how 18F-fluorodeoxyglucose (FDG), a radioactive sugar behaves in head and neck cancer (HNC) and inflammation immediately following injection and at many hours post-injection, with the world's first total-body positron emission tomography (PET)...
What is the current status of trial NCT05625217?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2023-02-27. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT05625217?
The interventions under investigation include: Total Body PET/CT Imagin (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05625217?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05625217's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI